Canada launches Sogroya: a pioneering once-weekly growth hormone treatment Canada has officially announced the commercialization of Sogroya® (somapacitan injection), marking a significant advancement in the treatment of growth hormone deficiency (GHD). As the first-and-only once-weekly growth hormone (GH) therapy indicated for both pediatric and adult patients, Sogroya® offers a convenient alternative to daily injections for…